Skip to main content
. Author manuscript; available in PMC: 2013 Sep 20.
Published in final edited form as: Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930

Figure 1. Rapid anti-tumor effects mediated by 19-28z T cells.

Figure 1

A. BM aspirates pre- and post-treatment with 19-28z T cells in 2 patients with morphologic chemotherapy-refractory B-ALL. Cyclophosphamide was given at Day −1 and CD19 CAR-targeted T cells were infused on Days 1 and 2. Left panels. BM prior to CAR modified T cell therapy demonstrated predominant blast cells with an absence of normal BM precursors. For MSK-ALL04 the left panel includes an inset with 100× magnification. Middle panels are BM aspirates done shortly after 19-28z T cell infusion and is hypocellular with normal stromal elements, histiocytes, and no evidence of blasts. Right panels. By 1 to 2 months after CAR modified T cell therapy there is BM recovery with normal hematopoiesis and no evidence of abnormal blasts. B. Flow cytometry for CD19 and CD10 expression in BM pre- and post-treatment. Cells were gated on CD45+7AAD− cells.